ArticleScientific reports2023
Bioprospecting for industrially relevant exopolysaccharide-producing cyanobacteria under Portuguese simulated climate.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 13 citations in OpenAlex.
- Genomic and chemical insights into a human lectin-binding extracellular polysaccharides from Parageobacillus toebii strain H-70.PloS one · 2026Article
- Cyanobacteria and Soil Restoration: Bridging Molecular Insights with Practical Solutions.Microorganisms · 2025Review
- Unveiling the Biotechnological Potential of Cyanobacteria from the Portuguese LEGE-CC Collection Through Lipidomics and Antioxidant and Lipid-Lowering Properties.Molecules (Basel, Switzerland) · 2025Article
- Recent progress in the cyanobacterial products and applications of phycocyanins.World journal of microbiology & biotechnology · 2025Review
- The need for smart microalgal bioprospecting.Natural products and bioprospecting · 2025Review
- Immunomodulatory properties of polysaccharide extract samples from Cyanobacterium sp. Rippka B-1200.Scientific reports · 2024Article
- Biomedical engineering utilizing living photosynthetic cyanobacteria and microalgae: Current status and future prospects.Materials today. Bio · 2024Review
- Immunomodulatory Compounds from the Sea: From the Origins to a Modern Marine Pharmacopoeia.Marine drugs · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyanobacterial exopolysaccharides (EPS) are potential candidates for the production of sustainable biopolymers. Although the bioactive and physicochemical properties of cyanobacterial-based EPS are attractive, their commercial exploitation is limited by the high production costs. Bioprospecting and characterizing novel EPS-producing strains for industrially relevant conditions is key to facilitate their implementation in various biotechnological applications and fields. In the present work, we selected twenty-five Portuguese cyanobacterial strains from a diverse taxonomic range (including some genera studied for the first time) to be grown in diel light and temperature, simulating the Portuguese climate conditions, and evaluated their growth performance and proximal composition of macronutrients. Synechocystis and Cyanobium genera, from marine and freshwater origin, were highlighted as fast-growing (0.1-0.2 g L
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.